Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 10/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.82 |
| ▸ | RAB9A | P51151 | 1/20 | 0.75 |
| ▸ | HTT | P42858 | 1/20 | 0.72 |
| ▸ | NPC1 | O15118 | 1/20 | 0.71 |
| ▸ | TP53 | P04637 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | THRB | P10828 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16557567 | 0.94 | HPGD (0.82) | HPGDALDH1A1RAB9AHTTNPC1 | |
| SCHEMBL16557462 | 0.91 | HPGD (0.70) | HPGDALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL15583871 | 0.91 | HPGD (1.00) | HPGDALDH1A1RAB9AHTTNPC1 | |
| SCHEMBL16557565 | 0.90 | HPGD (1.00) | HPGDALDH1A1RAB9AHTTNPC1 | |
| SCHEMBL16557566 | 0.90 | HPGD (0.81) | HPGDALDH1A1RAB9AHTTNPC1 | |
| SCHEMBL15583940 | 0.89 | HPGD (1.00) | HPGDALDH1A1RAB9AHTTTP53 | |
| SCHEMBL16557575 | 0.88 | POLB (0.81) | HPGDALDH1A1RAB9AHTTNPC1 | |
| SCHEMBL16557426 | 0.88 | MEN1 (0.71) | HPGDALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL15583802 | 0.87 | HPGD (0.84) | HPGDALDH1A1RAB9AHTTNPC1 | |
| SCHEMBL16560521 | 0.87 | HPGD (0.89) | HPGDALDH1A1RAB9AHTTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210032265-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-02-04 | — | — | US | disclosed |
| US-20200140453-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-05-07 | — | — | US | disclosed |
| US-10301320-B2 | Compositions and methods of modulating 15-PGDH activity | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2019-05-28 | — | — | US | disclosed |
| US-9790233-B2 | Compositions and methods of modulating 15-PGDH activity | CASE WESTERN RESERVE UNIVERSITY (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790233-B2 | Compositions and methods of modulating 15-PGDH activity | CASE WESTERN RESERVE UNIVERSITY (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170165241-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2017-06-15 | — | — | US | disclosed |
| US-20170165241-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2017-06-15 | — | — | US | disclosed |
| US-20150072998-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2015-03-12 | — | — | US | disclosed |
| US-20150072998-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2015-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170165241-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | PTGS1, HPGD, PTGIS | HPGD 2/4885ALDH1A1 415/4885RAB9A 3239/4885 |
| US-20200140453-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | PTGS1, HPGD, PTGIS | HPGD 2/4885ALDH1A1 415/4885RAB9A 3239/4885 |
| US-20150072998-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | PTGS1, HPGD, PTGIS | HPGD 2/4885ALDH1A1 415/4885RAB9A 3239/4885 |
| US-20210032265-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | PTGS1, HPGD, PTGIS | HPGD 2/4885ALDH1A1 415/4885RAB9A 3239/4885 |
| US-10301320-B2 | Compositions and methods of modulating 15-PGDH activity | PTGS1, HPGD, PTGIS | HPGD 2/4885ALDH1A1 415/4885RAB9A 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.